CD8A and neoplasm: Previous studies have shown that TILs (especially CD8+ TILs), which have anti-tumor activity, are associated with good prognosis in patients with tumors (Galon et al., 2006; Mahmoud et al., 2011; Hwang et al., 2012; Pages et al., 2005).